Wednesday, July 8, 2026

pharma · Phenylketonuria · Amyotrophic Lateral Sclerosis · PTCT

PTC THERAPEUTICS

PTC THERAPEUTICS is a pharma organization headquartered in WARREN, NJ, USA. It trades on NYSE under ticker PTCT. Primary therapeutic focus areas include Phenylketonuria, Amyotrophic Lateral Sclerosis, Cystic Fibrosis, Du

500 Warren Corporate Center Drive, Warren, NJ 07059, US HQ
1998 Founded
1,153 Employees
Public company Type
PTCT · NYSE Ticker
Company details
Status
Public
HQ
500 Warren Corporate Center Drive, Warren, NJ 07059, US
Founded
1998
Employees
1,153
Programs
52
Drugs
21
Patents
149
Clinical program

Eladocagene Exuparvovec

Phase 2 · gene therapy · AADC Deficiency

Eladocagene Exuparvovec for AADC Deficiency is a Phase 2 program (gene_therapy) at PTC THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).

← All PTC THERAPEUTICS, INC. projects Phase 2 gene therapy active

Internal code PTC-AADC-GT-002

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
PTC THERAPEUTICS, INC.
Phase
Phase 2
Modality
gene_therapy
Indication
AADC Deficiency
Status
active
Trials
1